Cyclin Dependent Like Kinase 5 (Serine/Threonine Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or Cell Division Protein Kinase 5 or CDK5 or EC 2.7.11.1) - Pipeline Review, H2 2017

  • ID: 4384097
  • Report
  • 48 pages
  • Global Markets Direct
1 of 5
Cyclin Dependent Like Kinase 5 (Serine/Threonine Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or Cell Division Protein Kinase 5 or CDK5 or EC 2.7.11.1) - Pipeline Review, H2 2017

Summary

According to the recently published report 'Cyclin Dependent Like Kinase 5 - Pipeline Review, H2 2017'; Cyclin Dependent Like Kinase 5 (Serine/Threonine Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or Cell Division Protein Kinase 5 or CDK5 or EC 2.7.11.1) pipeline Target constitutes close to 6 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes.

Cyclin Dependent Like Kinase 5 (Serine/Threonine Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or Cell Division Protein Kinase 5 or CDK5 or EC 2.7.11.1) - Cell division protein kinase 5 is an enzyme encoded by the CDK5 gene. It does not directly control cell cycle regulation. Instead it functions in diverse processes such as synaptic plasticity and neuronal migration through phosphorylation of proteins required for cytoskeletal organization, endocytosis and exocytosis, and apoptosis. Dysregulation of this enzyme is involved in several neurodegenerative diseases including Alzheimer's disease and invasive cancers.

The report 'Cyclin Dependent Like Kinase 5 - Pipeline Review, H2 2017' outlays comprehensive information on the Cyclin Dependent Like Kinase 5 (Serine/Threonine Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or Cell Division Protein Kinase 5 or CDK5 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Cyclin Dependent Like Kinase 5 (Serine/Threonine Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or Cell Division Protein Kinase 5 or CDK5 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I and Preclinical stages are 1, 1 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Oncology and Metabolic Disorders which include indications Alzheimer's Disease, Breast Cancer, Solid Tumor, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Amyotrophic Lateral Sclerosis, Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-Cell Lymphoma, Lung Cancer, Multiple Myeloma (Kahler Disease), Multiple Sclerosis, Neuroblastoma, Obesity, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, Type 2 Diabetes and Uterine Cancer.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Cyclin Dependent Like Kinase 5 (Serine/Threonine Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or Cell Division Protein Kinase 5 or CDK5 or EC 2.7.11.1)
  • The report reviews Cyclin Dependent Like Kinase 5 (Serine/Threonine Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or Cell Division Protein Kinase 5 or CDK5 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Cyclin Dependent Like Kinase 5 (Serine/Threonine Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or Cell Division Protein Kinase 5 or CDK5 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Cyclin Dependent Like Kinase 5 (Serine/Threonine Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or Cell Division Protein Kinase 5 or CDK5 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Cyclin Dependent Like Kinase 5 (Serine/Threonine Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or Cell Division Protein Kinase 5 or CDK5 or EC 2.7.11.1) targeted therapeutics
Reasons to Buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Cyclin Dependent Like Kinase 5 (Serine/Threonine Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or Cell Division Protein Kinase 5 or CDK5 or EC 2.7.11.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Cyclin Dependent Like Kinase 5 (Serine/Threonine Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or Cell Division Protein Kinase 5 or CDK5 or EC 2.7.11.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5
Introduction

Cyclin Dependent Like Kinase 5 (Serine/Threonine Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or Cell Division Protein Kinase 5 or CDK5 or EC 2.7.11.1) - Overview

Cyclin Dependent Like Kinase 5 (Serine/Threonine Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or Cell Division Protein Kinase 5 or CDK5 or EC 2.7.11.1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Cyclin Dependent Like Kinase 5 (Serine/Threonine Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or Cell Division Protein Kinase 5 or CDK5 or EC 2.7.11.1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cyclin Dependent Like Kinase 5 (Serine/Threonine Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or Cell Division Protein Kinase 5 or CDK5 or EC 2.7.11.1) - Companies Involved in Therapeutics Development

Cyclacel Pharmaceuticals Inc

Cyclin Dependent Like Kinase 5 (Serine/Threonine Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or Cell Division Protein Kinase 5 or CDK5 or EC 2.7.11.1) - Drug Profiles

CT-526 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CYC-065 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sapacitabine + seliciclib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CDK1, CDK5 and GSK3b for Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Inhibit CDK5 for CNS and Metabolic Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TP-5 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cyclin Dependent Like Kinase 5 (Serine/Threonine Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or Cell Division Protein Kinase 5 or CDK5 or EC 2.7.11.1) - Dormant Products

Cyclin Dependent Like Kinase 5 (Serine/Threonine Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or Cell Division Protein Kinase 5 or CDK5 or EC 2.7.11.1) - Discontinued Products

Cyclin Dependent Like Kinase 5 (Serine/Threonine Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or Cell Division Protein Kinase 5 or CDK5 or EC 2.7.11.1) - Product Development Milestones

Featured News & Press Releases

Aug 07, 2017: Cyclacel Announces Selection of Recommended Phase 2 Dose for CYC065 and Evidence of Durable Target Engagement and Mcl-1 Biomarker Suppression

Apr 02, 2017: Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, Elicits Marked Antineoplastic Effects in Lung Cancer by Engaging Anti-Metastatic Pathways

Mar 07, 2017: Cyclacels CDK Inhibitor CYC065 Causes Anaphase Catastrophe, a Novel Cancer-Specific Mechanism of Action, in Research Published in JNCI

Sep 06, 2016: Cyclacel's CYC065 Demonstrates Promising Activity in MYCN-Addicted Neuroblastoma in Preclinical Data Presented at Childhood Cancer

Aug 02, 2016: Cyclacel CYC065 Demonstrates Promising Activity in Uterine Serous Carcinoma in Preclinical Data Published by Independent Academic Researchers

Jun 06, 2016: Cyclacel Reports Updated Data From Its DNA Damage Response Program on Seliciclib and Sapacitabine Combination in Patients With Solid Tumors at ASCO

May 19, 2016: Cyclacel’s Seliciclib-Sapacitabine Abstract Selected for Oral Presentation at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 18, 2016: Cyclacel’s Second-Generation CDK2/9 Inhibitor, CYC065, is an Effective Inducer of Cell Death in B-cell Lymphoma and Synergizes With Bcl-2 or BET Inhibitors

Dec 14, 2015: Molecular Basis for Development of Cyclacel’s CYC065 CDK2/9 Inhibitor in Triple-Negative Breast Cancer Presented at San Antonio Breast Cancer Symposium

Nov 23, 2015: CYC065, Cyclacel's Novel CDK2/9 Inhibitor, Prolongs Survival in MYCN-Addicted Neuroblastoma Models

Nov 09, 2015: Mechanistic Rationale for CYC065, Cyclacel's CDK2/9 Inhibitor, in Targeted Solid Tumors and Hematological Malignancies Presented at AACR-NCI-EORTC International Conference

Oct 26, 2015: Data to be Presented on CYC065, Cyclacel's CDK2/9 Inhibitor, at AACR-NCI-EORTC International Conference

Oct 22, 2015: Cyclacel Doses First Patient in Phase 1 Trial of Its Novel CDK2/9 Inhibitor, CYC065, for the Treatment of Advanced Solid Tumors

Sep 17, 2015: Cyclacel Presents Molecular Rationale for Clinical Development of CYC065 CDK Inhibitor in Leukemias and Lymphomas

Apr 20, 2015: Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, Demonstrates Therapeutic Potential and Synergy With Other Anti-Cancer Compounds

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H2

Number of Products under Development by Therapy Areas, H2

Number of Products under Development by Indication, H2

Number of Products under Development by Companies, H2

Products under Development by Companies, H2

Number of Products under Investigation by Universities/Institutes, H2

Products under Investigation by Universities/Institutes, H2

Number of Products by Stage and Mechanism of Actions, H2

Number of Products by Stage and Route of Administration, H2

Number of Products by Stage and Molecule Type, H2

Pipeline by Cyclacel Pharmaceuticals Inc, H2

Dormant Projects, H2

Discontinued Products, H2

List of Figures

Number of Products under Development by Stage of Development, H2

Number of Products under Development by Therapy Areas, H2

Number of Products under Development by Top 10 Indications, H2

Number of Products by Stage and Mechanism of Actions, H2

Number of Products by Routes of Administration, H2

Number of Products by Stage and Routes of Administration, H2

Number of Products by Molecule Types, H2

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Cyclacel Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll